Advisory Board Members

Our advisory board is composed of premiere professionals representing critical areas across the healthcare continuum.

Michael Null

Business Development / M&A

Michael’s career has been defined by a deep commitment to achieving desired outcomes and exits through effective leadership, teamwork, and strategic decision-making. He has a proven record working with private equity investors and senior leadership teams to develop and execute profitable commercial strategies. His expertise includes buy-side acquisitions, business development, personalized medicine, contract research services for discovery of new drugs and diagnostics, anatomic pathology, artificial intelligence, and molecular testing services.

At Aurora Diagnostics, Michael was one of five executives that participated in the sale process of Aurora in 2019, culminating in a successful acquisition by Sonic Healthcare for $540 million. Subsequently, was promoted to the position of Chief Commercial Officer for the Sonic AP Division, overseeing sales, marketing, and business integration.  Managing a P&L of $6.8 million and team of over 100 employees, Michael developed and implemented sales and marketing strategies, product development, and commercial leadership. He was instrumental in the rebranding of 37 laboratories, further solidifying Sonic Healthcare’s market presence.

As President of the Aurora Research Institute (ARI), Michael spearheaded the development and execution of a successful business plan and founded ARI, leveraging their laboratory testing infrastructure and pathology expertise to generate over $45 million in revenue and $19.8 million in EBITDA through 1000 research projects. During his leadership ARI exceeded annual revenue and EBITDA targets, achieving a remarkable CAGR of 19.3% from 2015 to 2021.

Prior to role, as Executive Vice President of Sales & Marketing, Michael played a pivotal role in the growth of Aurora Diagnostics, growing it to become the largest anatomic pathology company in the United States, generating $350 million in revenue and $58 million in EBITDA.